A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

Last updated:
2026-09-12
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ADJUNCTIVE TREATMENT WITH BRENIPATIDE IN DELAYING TIME TO RELAPSE COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH MAJOR DEPRESSIVE DISORDER (RENEWMDD-2)

Intervention/treatment:
BRENIPATIDE (LY3537031)
Medical condition:
MAJOR DEPRESSIVE DISORDER
Protocol code:
J2S-MC-GZMI
Control number:
504687
Status:
Not yet recruiting
Approved:
September 08, 2026
Trial phase:
Phase 3
For more information:
ClinicalTrials.gov - NCT07775300
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 75 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Role
CONTACT
Phone:
1-317-615-4559
Name
Physicians interested in becoming principal investigators please contact
Role
CONTACT
Sponsor
ELI LILLY CANADA INC

Locations

Alpha Recherche Clinique
Québec, G2J 0C4
Role
CONTACT
Phone:
418-704-1112
Name
Raphael Poulin-Robitaille
Role
PRINCIPAL_INVESTIGATOR
ALPHA Recherche Clinique
Québec, G3K 2P8
Role
CONTACT
Phone:
418-847-1112
Name
Xavier Mignault
Role
PRINCIPAL_INVESTIGATOR
Alpha Recherche Clinique - Lévis
Lévis, G6V 0C9
Role
CONTACT
Phone:
418-380-1112
Name
Steeve Kwan Tat
Role
PRINCIPAL_INVESTIGATOR
AMNDX
Markham, L3R 1A3
Role
CONTACT
Phone:
647-984-8882
Name
Alan Lowe
Role
PRINCIPAL_INVESTIGATOR
CaRe Clinic
Calgary, T2N 4L7
Role
CONTACT
Phone:
1-587-955-3401
Name
Payman Hajiazim
Role
PRINCIPAL_INVESTIGATOR
Kelowna Health and Memory Centre
Kelowna, V1Y 5A8
Name
Eugene Okorie
Role
PRINCIPAL_INVESTIGATOR
Malton Medical Group
Mississauga, L4T 4J2
Role
CONTACT
Phone:
905-677-4200
Name
Brian Zidel
Role
PRINCIPAL_INVESTIGATOR
Providence Care
Kingston, K7L 4X3
Role
CONTACT
Phone:
6135444900
Name
Roumen Milev
Role
PRINCIPAL_INVESTIGATOR
Research, Innovation, Science and Excellence (RISE) Institute
Toronto, L5L 1W8
Role
CONTACT
Phone:
4166695279
Name
Roger McIntyre
Role
PRINCIPAL_INVESTIGATOR
Richmond Clinical Trials
Richmond, V6V 2L1
Role
CONTACT
Phone:
604-373-4954
Name
Harris Lari
Role
PRINCIPAL_INVESTIGATOR
Did you find what you were looking for?

Contacts and resources